| Literature DB >> 31075110 |
Naeem Mubarak1,2, Ernieda Hatah3, Mohd Aznan Md Aris4, Asrul Akmal Shafie5, Che Suraya Zin1.
Abstract
BACKGROUND: The general problem is lack of inter-professional collaboration and the way private primary care responds to manage chronic diseases in Malaysia. Absence of prescription review, inadequate patient education, the highest percentage of prescribing errors and half of the chronic disease patients are nonadherent. Medicines are the most common and life long used interventions in chronic diseases. Hence, the need to manage medicine in chronic diseases becomes obligatory. As both general practitioner and community pharmacist can dispense medications, this has resulted in a business rivalry. There is a need to build consensus among various healthcare stakeholders for a collaborative medication therapy management model (CMTM) where community pharmacist has an active role in chronic care.Entities:
Mesh:
Year: 2019 PMID: 31075110 PMCID: PMC6510413 DOI: 10.1371/journal.pone.0216563
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The Delphi process.
CP = community pharmacist, GP = general practitioner, CMTM = Collaborative Medication Therapy Management, IQR = interquartile range, ICC = intra-class correlation coefficient, QP = QuestionPro, MS = Microsoft.
Fig 2Expert selection flowchart (modified from [35]).
MREC = Medical Research & Ethics Committee, KRNW = Knowledge Resource Nomination Worksheet, GP = general practitioner, CP = community pharmacist, MoH = Ministry of Health, MHE = Ministry of Higher Education, MPS = Malaysian Pharmaceutical Society, FMS = Family Medicine Specialist, MMC = Malaysian Medical Council, MMA = Malaysian Medical Association.
Response and completion rate of experts in 1st and 2nd round.
| Rounds | Category of experts | Invited | Agreed | Completed | Response Rate | Completion Rate (%) |
|---|---|---|---|---|---|---|
| GP | 16 | 14 | 11 | 68.75 | 78.57 | |
| CP | 11 | 11 | 10 | 90.91 | 90.91 | |
| Nurse | 11 | 10 | 8 | 72.73 | 80.00 | |
| GP | 11 | 11 | 11 | 100% | 100% | |
| CP | 10 | 10 | 10 | 100% | 100% | |
| Nurse | 8 | 8 | 8 | 100% | 100% | |
% = percentage, n = number of experts, CP = community pharmacist, GP = general practitioner.
Fig 3Geographical diversity of Delphi experts in this study across Malaysia.
Demographics of Delphi experts.
| Characteristics | Category | n (%) | |||
|---|---|---|---|---|---|
| GP | CP | Nurse | Total | ||
| Male | 5 (17.2) | 7 (24.1) | 3 (10.3) | 15 (51.72) | |
| Female | 6 (20.7) | 3 (10.3) | 5 (17.2) | 14 (48.28) | |
| Yes | 7 (24.1) | 3 (10.3) | 7 (24.1) | 17 (58.62) | |
| No | 4 (13.8) | 7 (24.1) | 1 (3.4) | 12 (41.38) | |
| Local | 5 (17.2) | 5 (17.2) | 5 (17.2) | 15 (51.72) | |
| Both Local and International | 6 (20.7) | 5 (17.2) | 3 (10.3) | 14 (48.28) | |
| Yes | 8 (27.59) | - | 8 (27.59) | 16 (55.17) | |
| No | 3 (10.34) | - | - | 3 (10.34) | |
| - | - | 10 (34.48) | - | 10 (34.48) | |
| Yes | - | 8 (27.59) | 8 (27.59) | 16 (55.17) | |
| No | - | 2 (6.9) | 0 | 2 (6.9) | |
| - | 11 (37.93) | - | - | 11 (37.93) | |
| Professor | 2 (6.9) | 2 (6.9) | 0 | 4 (13.79) | |
| Associate Professor | 4 (13.79) | 1 (3.45) | 1 (3.45) | 6 (20.68) | |
| Assistant Professor | 2 (6.9) | 0 | 3 (10.34) | 5 (17.24) | |
| Not in academia | 3 (10.34) | 7 (24.14) | 4 (13.79) | 14 (48.27) | |
| PhD | 2 (6.9) | 3 (10.34) | 3 (10.34) | 8 (27.59) | |
| Specialization (MRCP) | 1 (3.45) | - | - | 1 (3.45) | |
| MD | 2 (6.9) | - | - | 2 (6.9) | |
| Master | 6 (20.69) | 2 (6.9) | 5 (17.24) | 13 (44.83) | |
| Bachelor | 0 | 5 (17.24) | 0 | 5 (17.24) | |
| - | 52 (45–59) | 50 (45–62) | 46 (40–55) | 50 (40–62) | |
| - | 24 (17–32) | 27.5 (20–39) | 21 (17–27) | 24 (17–39) | |
*Median (Range) is given for age and total experience.
GP = general practitioner, CP = community pharmacist, nt = total number of experts, n = number of experts.
Consensus among experts in both rounds (based on percentage sum of agree and strongly agree) and stability in response of experts between rounds.
| Theme | Sr. | Statements | Round | Median | (%) (A+SA) | P/ F | Wilcoxon |
|---|---|---|---|---|---|---|---|
| 1. | Currently in Malaysia, there is no collaboration between CP and GP for patient-centered care services (e.g., CMTM) for chronic disease(s). | 1st | 4 (1) | 86.21 | P | 0.976 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 2. | The new models of patient-centered community pharmacy services (which involve close collaboration between CP and GP) may help in reducing the incidence of drug related problems in patients with chronic disease(s). | 1st | 5 (1) | 79.31 | F | 1.00 | |
| 2nd | 5 (1) | 86.21 | P | ||||
| 3. | In Malaysia, the potential of CP in delivering patient-centered care (through CMTM services) is underutilized, leading to resource wasting. | 1st | 4 (2) | 75.86 | F | 0.648 | |
| 2nd | 4 (1) | 82.76 | F | ||||
| 4. | Taking example from developed countries, Malaysia should utilize the CP’s potentials in delivering patient-centered care services. | 1st | 5 (1) | 89.66 | P | 0.808 | |
| 2nd | 5 (1) | 89.66 | P | ||||
| 5. | Considering the needs of aging population, it is the right time to focus on patient-centered collaborative care practice between CP and GP in Malaysia. | 1st | 5 (1) | 96.55 | P | 0.739 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 6. | National survey on the use of medicines by Malaysian consumers, 2012 implied on the dire need for patient education in view of high percentage (56%) of patients who were not aware of the proper use and common side effects of their medications | 1st | 5 (1) | 89.65 | P | 0.796 | |
| 2nd | 5 (1) | 89.65 | P | ||||
| 7. | In the current practice of primary health care model, lack of patient’s motivation is one of the reasons of poor compliance to medicines in chronic disease(s). | 1st | 4 (0) | 82.76 | F | 1.00 | |
| 2nd | 4 (0) | 89.66 | P | ||||
| 8. | To achieve therapeutic goals, there is a need of motivation to improve patient compliance with the medications used in chronic diseases. | 1st | 5 (1) | 96.55 | P | 0.637 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 9. | In the current primary health care model in Malaysia, there is no ″prescription review″ process which may serve as a second security layer to alarm prescription errors or inappropriate medicine use. | 1st | 4 (1) | 82.76 | F | 0.860 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 10. | When ″prescription review″ will be embedded in system, many drug related problems/errors would be preventable. | 1st | 5 (1) | 100 | P | 0.782 | |
| 2nd | 5 (1) | 100 | P | ||||
| 11. | Absence of ″prescription review″ process may increase the risk for prescriber’s malpractice, such as over prescribing of medications to increase profit margin. | 1st | 5 (1) | 89.65 | P | 0.973 | |
| 2nd | 5 (1) | 89.65 | P | ||||
| 12. | Absence of CP-GP collaboration is disadvantageous for the patients, because patients lose out a protective layer on prescribing (i.e., prescription review by CP). | 1st | 4 (1) | 89.66 | P | 0.973 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 13. | Absence of CP-GP collaboration is disadvantageous for the individual patient, because of limited education he receives from a single care-provider (GP) due to high number of patients in GPs’ clinics. | 1st | 4 (2) | 72.42 | F | 0.904 | |
| 2nd | 4 (2) | 68.97 | F | ||||
| 14. | Without collaborative practice, CPs and GPs may not have the advantage of utilizing each other's expertise in patient-care. | 1st | 4 (1) | 93.11 | P | 1.00 | |
| 2nd | 4 (1) | 93.11 | P | ||||
| 15. | Absence of collaboration between CP and GP is disadvantageous for the Government, because patients miss the proper education on medication use and/or disease management, which may result in wastage of healthcare resources, for example, due to hospitalization and emergency department visits. | 1st | 5 (1) | 89.65 | P | 0.614 | |
| 2nd | 5 (1) | 89.65 | P | ||||
| 16. | In a broader view, GP and CP share common objectives in patient care. | 1st | 5 (1) | 96.55 | P | 1.00 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 17. | In Malaysia, growing health related problems associated with aging population & chronic diseases can be addressed more effectively by a well-structured patient-centered collaborative practice (in the form of CMTM) between CP and GP. | 1st | 5 (1) | 93.1 | P | 1.00 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 18. | In Malaysia, CP and GP should work together in managing chronic disease(s). | 1st | 5 (1) | 93.11 | P | 0.963 | |
| 2nd | 5 (1) | 93.11 | P | ||||
| 19. | CP may enhance GP’s evidence-based medicine practice by providing them important information on medicine use, such as its benefits and risks. | 1st | 4 (1) | 89.65 | P | 0.936 | |
| 2nd | 4 (1) | 89.65 | P | ||||
| 20. | CP may have role in the prescription review which involves identifying and preventing prescription or prescribing errors, such as related to drug interactions or any contraindication. | 1st | 5 (1) | 96.55 | P | 0.808 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 21. | CP may have role in suggesting GP on alteration in patients’ drug therapy | 1st | 4 (1) | 82.76 | F | 0.833 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 22. | CP may have role in advising GP on cost-effective prescribing. | 1st | 5 (1) | 89.65 | P | 0.981 | |
| 2nd | 5 (1) | 89.65 | P | ||||
| 23. | Compared with GP’s assistant, CP can provide patients a more rational advice on the use of medicines based on his training and knowledge of pharmacology. | 1st | 5 (1) | 96.55 | P | 1.00 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 24. | CP may counsel patients about what to expect from their medicine including its expected pharmacological effects and side- effects. | 1st | 4 (1) | 96.56 | P | 1.00 | |
| 2nd | 4 (1) | 96.56 | P | ||||
| 25. | CP may help in improving patients’ compliance/adherence to medicines by providing an adherence plan to patients. | 1st | 5 (1) | 96.55 | P | 0.803 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 26. | CP may dispense repeat prescriptions for a patient as per agreed protocols and contacting the GP if a problem arises. | 1st | 5 (1) | 96.55 | P | 0.967 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 27. | CP may perform dosing adjustments to a patient’s medicine using agreed protocols established with GP. | 1st | 4 (1) | 82.76 | F | 0.948 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 28. | CMTM service would improve CP-GP effective communication about patient’s drug therapy | 1st | 4 (1) | 96.56 | P | 1.00 | |
| 2nd | 4 (1) | 96.56 | P | ||||
| 29. | The two-way communication (established under CMTM) between CP-GP would result in improved patient care. | 1st | 5 (1) | 82.76 | F | 0.805 | |
| 2nd | 5 (1) | 86.21 | P | ||||
| 30. | Collaborative practice like CMTM offers GP to utilize CP’s expertise in pharmacotherapy. | 1st | 5 (1) | 93.1 | P | 1.00 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 31. | CMTM service offers patients to take benefits from CP’s drug expertise at a highly accessible position (community pharmacy). | 1st | 5 (1) | 93.1 | P | 1.00 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 32. | CMTM service may improve patient’s clinical outcomes (through its medication therapy review and patient action plan development). | 1st | 4 (1) | 89.65 | P | 0.564 | |
| 2nd | 4 (1) | 89.65 | P | ||||
| 33. | CMTM service may improve patient’s knowledge on self-management of disease (i.e., self-care; how to avoid adverse event or exacerbation). | 1st | 5 (1) | 89.65 | P | 0.627 | |
| 2nd | 5 (1) | 89.65 | P | ||||
| 34. | CMTM service may improve patient’s knowledge on rational use of medicines. | 1st | 4 (1) | 89.66 | P | 0.627 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 35. | CMTM may significantly reduce hospital/emergency admissions by improving patients’ understanding on disease and its management. | 1st | 4 (1) | 79.31 | F | 1.00 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 36. | CMTM practice may encourage cost-effective prescribing which may reduce patients’ cost of treatment. | 1st | 4 (1) | 93.11 | P | 0.851 | |
| 2nd | 4 (1) | 93.11 | P | ||||
| 37. | Patient’s personal medication record (in CMTM) may serve as an early warning system to alarm CP about any under or over-use of medicine by patient. | 1st | 4 (1) | 89.66 | P | 1.00 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 38. | CMTM service will include a ″prescription review″ process by CP, which may help to ensure patients’ safety by preventing any prescription or prescribing error. | 1st | 5 (1) | 100 | P | 1.00 | |
| 2nd | 5 (1) | 100 | P | ||||
| 39. | CMTM service may reduce medicine waste by improving patient’s compliance to their medicine. | 1st | 4 (1) | 89.66 | P | 0.851 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 40. | CMTM like service by CP in Malaysia could help patients to better manage their medicine. | 1st | 4 (1) | 93.11 | P | 0.378 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 41. | In Malaysia, involving CP in CMTM would be an appropriate way to prevent human resource waste i.e., the underutilized CP. | 1st | 4 (1) | 82.76 | F | 0.599 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 42. | In Malaysia, involving CP in collaborative practice would help them in their own professional development. | 1st | 4 (1) | 93.1 | P | 1.00 | |
| 2nd | 4 (1) | 93.1 | P | ||||
| 43. | In Malaysia, CP-GP collaboration in CMTM will create opportunities of transition to a value-based health care delivery system. | 1st | 4 (1) | 93.1 | P | 1.00 | |
| 2nd | 4 (1) | 93.1 | P | ||||
| 44. | Protocol and terms of collaboration between CP and GP must be drafted and agreed beforehand. | 1st | 5 (1) | 96.55 | P | 1.00 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 45. | CP and GP must be accredited (by their respective regulatory bodies) to provide the collaborative service to patients. | 1st | 5 (1) | 93.1 | P | 1.00 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 46. | The service would only be provided after approval of Ministry of Health and/or Pharmaceutical division. | 1st | 4 (1) | 79.31 | F | 0.820 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 47. | Patients’ recruitment in the CMTM service needs to be done through a referral system (GP to CP and vice versa), for example, through a formal patient’s referral letter. | 1st | 5 (1) | 79.31 | F | 0.672 | |
| 2nd | 5 (1) | 86.2 | P | ||||
| 48. | Participation in the CMTM service must be with patients’ consent. | 1st | 5 (1) | 93.1 | P | 0.796 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 49. | Phone may be the best way to communicate for such collaborative practice. | 1st | 4 (1) | 62.07 | F | 0.934 | |
| 2nd | 4 (1) | 62.07 | F | ||||
| 50. | In addition to phone communication, at least one monthly face to face CP-GP meeting should be necessary. | 1st | 4 (1) | 72.41 | F | 0.724 | |
| 2nd | 4 (1) | 75.86 | F | ||||
| 51. | The communication between CP-GP should always ensure protection over patients’ private and confidential information. | 1st | 5 (1) | 96.55 | P | 0.813 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 52. | CMTM collaborative services should be allowed only for patients with chronic disease(s), such as hypertension, asthma and diabetes. | 1st | 4 (3) | 55.17 | F | 0.527 | |
| 2nd | 4 (3) | 62.07 | F | ||||
| 53. | As a start CPs and GPs should be allowed to recruit only a certain number of patients into the service in a year. | 1st | 4 (2) | 75.87 | F | 0.658 | |
| 2nd | 4 (1) | 79.31 | F | ||||
| 54. | CP and GP must allow practice of sharing important patients’ information to each other. | 1st | 4 (1) | 79.31 | F | 0.847 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 55. | CP must document all the consultations and/or interventions performed. | 1st | 5 (1) | 96.55 | P | 0.822 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 56. | CP must communicate all interventions to GP on a structured CP’s interventions form. | 1st | 5 (1) | 96.55 | P | 0.822 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 57. | Hypertension | 1st | 5 (1) | 96.55 | P | 1.00 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 58. | Asthma/COPD | 1st | 5 (1) | 96.56 | P | 1.00 | |
| 2nd | 5 (1) | 96.56 | P | ||||
| 59. | Diabetes | 1st | 5 (1) | 96.55 | P | 1.00 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 60. | Depression | 1st | 4 (2) | 51.72 | F* | 0.793 | |
| 2nd | 4 (2) | 58.62 | F | ||||
| 61. | AIDS | 1st | 3 (2) | 34.48 | F | 0.981 | |
| 2nd | 3 (2) | 34.48 | F | ||||
| 62. | Cancer | 1st | 3 (3) | 41.38 | F | 0.762 | |
| 2nd | 3 (3) | 41.38 | F | ||||
| 63. | There should be a ''CP-GP Collaborative Practice Agreement'' that defines roles, jurisdictions and terms of CP-GP collaborative practice. | 1st | 5 (1) | 96.55 | P | 0.796 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 64. | Existence of formal agreements would be an effective way for the development and maintenance of successful collaboration. | 1st | 4 (1) | 96.56 | P | 0.782 | |
| 2nd | 4 (1) | 96.56 | P | ||||
| 65. | These agreements will prevent concerns regarding role encroachment. | 1st | 4 (1) | 96.56 | P | 0.782 | |
| 2nd | 4 (1) | 96.56 | P | ||||
| 66. | These agreements will prevent concerns regarding delivery of contradictory messages to the patients | 1st | 5 (1) | 96.55 | P | 0.822 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 67. | These agreements should be established, both at professional organizations' level (Malaysian Pharmaceutical Society and Malaysian Medical Association) and at an official level (Ministry of Health). | 1st | 5 (1) | 93.1 | P | 0.952 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 68. | Collaboration between CP & GP can be initiated by mutual role recognition and respect. | 1st | 5 (1) | 100 | P | 0.796 | |
| 2nd | 5 (1) | 100 | P | ||||
| 69. | Regular communication between CP and GP may help in building rapport and trust. | 1st | 5 (1) | 100 | P | 0.796 | |
| 2nd | 5 (1) | 100 | P | ||||
| 70. | There should always be direct communication (face to face, telephone, email) between CP and GP about patients (communication should not be passed through patient to avoid misunderstanding). | 1st | 5 (1) | 96.55 | P | 0.822 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 71. | Joint (CP-GP) continuing professional education’s event or training may strengthen the collaborative service. | 1st | 4 (1) | 93.11 | P | 0.830 | |
| 2nd | 4 (1) | 93.11 | P | ||||
| 72. | Inter-professional module/course should be embedded as a mandatory component in health professional’s degree curriculum. | 1st | 5 (1) | 100 | P | 1.00 | |
| 2nd | 5 (1) | 100 | P | ||||
| 73. | Before starting the service, CP should officially get a mandatory accredited training/diploma/course on CMTM service for a specific chronic disease (asthma, diabetes, hypertension). | 1st | 4 (1) | 97.11 | P | 0.842 | |
| 2nd | 4 (1) | 93.11 | P | ||||
| 74. | Accreditation must include evaluation of CP’s competencies, such as clinical knowledge and communication skills (with both GP and patients). | 1st | 4 (1) | 96.55 | P | 0.973 | |
| 2nd | 4 (1) | 96.55 | P | ||||
| 75. | CP’s accreditation training/diploma/course would be a joint venture of Malaysian Pharmaceutical Society and Malaysian Medical Association under regulations of Ministry of Health, Malaysia. | 1st | 4 (1) | 93.1 | P | 0.837 | |
| 2nd | 4 (1) | 93.1 | P | ||||
| 76. | Accredited CP may be called ″consultant pharmacist″ or ″Community Pharmacist Practitioner″, would only be eligible to join these collaborative services for public. | 1st | 4 (1) | 89.66 | P | 0.976 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 77. | Such accreditation should be renewed after a certain duration that deems appropriate. | 1st | 4 (1) | 82.76 | F | 0.812 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 78. | The curriculum for undergraduate pharmacy degree should be made compulsory to include module for patient-centered collaborative practice, i.e., CMTM. | 1st | 5 (1) | 100 | P | 1.00 | |
| 2nd | 5 (1) | 100 | P | ||||
| 79. | After accreditation, continuing professional development/education for CPs may help to further boost their confidence to participate in the changing paradigm in health care delivery (CMTM practice). | 1st | 5 (1) | 96.55 | P | 0.819 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 80. | Pharmacy should have a counselling room or adequate private consultation space to conduct the CMTM service. | 1st | 4 (1) | 89.65 | P | 0.806 | |
| 2nd | 4 (1) | 89.65 | P | ||||
| 81. | Community pharmacy needs to have appropriate national standards against which CMTM service provision and the clinical care provided could objectively be judged. This would help public to make its own judgement about what to expect of the “best” services, when they visit any pharmacy. | 1st | 4 (1) | 96.55 | P | 0.782 | |
| 2nd | 4 (1) | 96.55 | P | ||||
| 82. | Community pharmacy should be officially categorized and advertised for its scope and area of practice (type of services it offers, i.e., essential and advance). | 1st | 4 (1) | 86.21 | P | 0.858 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 83. | An electronic national prescription database system should be developed under Ministry of Health to store the prescription records of all the chronic disease patients. | 1st | 5 (1) | 93.1 | P | 0.825 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 84. | The pharmacy offering CMTM service must have all the means which enables it to connect to national prescription database system to store prescriptions record, such as computer, server, data storage software and internet. | 1st | 5 (1) | 93.1 | P | 0.833 | |
| 2nd | 5 (1) | 93.1 | P | ||||
| 85. | High dispensary workloads of CP (involved in CMTM service) can be reduced by delegating clerical tasks (e.g., patient identification, appointment scheduling, billing) to pharmacy technicians/clerical staff. | 1st | 4 (1) | 96.55 | P | 0.957 | |
| 2nd | 4 (1) | 96.55 | P | ||||
| 86. | The service should be granted to CP with a pre-set number of patients seen per year based on CP’s ability to cater the service, such as manpower and infrastructure. | 1st | 4 (0) | 82.76 | F | 0.782 | |
| 2nd | 4 (0) | 82.76 | F | ||||
| 87. | In Malaysia, pharmacists are adequate to cater the public health needs. | 1st | 3 (2) | 48.28 | F | 0.545 | |
| 2nd | 4 (2) | 58.62 | F | ||||
| 88. | Campaign such as ″Know your medicine by asking your pharmacist″ may help to increase public awareness of the appropriate use of medicines. | 1st | 4 (1) | 89.66 | P | 0.768 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 89. | To promote public awareness about the importance of CMTM, Government should run a national level campaign to explain the advantages of collaborative practice between CP & GP. | 1st | 5 (1) | 96.55 | P | 0.813 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 90. | CP should be adequately compensated for providing CMTM services. | 1st | 4 (1) | 82.76 | F | 1.00 | |
| 2nd | 4 (1) | 86.21 | P | ||||
| 91. | A standard fee structure that is deem appropriate for collaborative CMTM should be determined by authorities, such as Malaysian Pharmaceutical Society and Ministry of Health, Malaysia to avoid profiteering. | 1st | 4 (1) | 93.1 | P | 0.830 | |
| 2nd | 4 (1) | 93.1 | P | ||||
| 92. | The burden of additional consultation fee for CMTM services may be minimized by Government subsidies. | 1st | 4 (2) | 75.86 | F | 0.653 | |
| 2nd | 4 (1) | 79.31 | F | ||||
| 93. | The Government should support a pilot study to evaluate effectiveness, potential issues and concerns raise for community pharmacy based CMTM service. | 1st | 5 (1) | 96.55 | P | 0.655 | |
| 2nd | 5 (1) | 96.55 | P | ||||
| 94. | After the pilot study, to avoid any economic setbacks, the CMTM can be gradually implemented in major cities in Malaysia. | 1st | 4 (1) | 82.76 | F | 0.467 | |
| 2nd | 4 (1) | 89.66 | P | ||||
| 95. | Collaboration between CP and GP can be achieved even without dispensing separation as it does not matter where a patient is getting medicines because at the end he would be seeing a CP. | 1st | 2 (2) | 37.93 | F | 0.821 | |
| 2nd | 2 (2) | 37.93 | F | ||||
| 96. | The objective of this collaboration is not to emphasize on selling drugs to make profits but to improve public health outcomes and reduce cost of therapy. | 1st | 5 (1) | 96.55 | P | 0.822 | |
| 2nd | 5 (1) | 96.55 | P |
CP = community pharmacist, GP = general practitioner, CMTM = Collaborative Medication Therapy Management, COPD = Chronic Obstructive Pulmonary Disease, AIDS = Acquired Immune Deficiency Syndrome, IQR = interquartile range, UHC = Universal Health Coverage, P = pass, F = fail, Q1 and Q3 = quartiles, A = agree, SA = strongly agree, % = percentage. Passed statements are those where conditions of consensus met as described in methods.
*F denotes the statements that failed to reach consensus (≥85%) in 1st round.
**F denotes the statements that failed to reach consensus (≥85%) in 2nd round.
Consensus among experts in both rounds for ranking statements and stability in response of experts between rounds for mean rank and priority order.
| Theme | Sr. | Statements | Round | Median | Mean Rank | Priority order | Wilcoxon |
|---|---|---|---|---|---|---|---|
| 1. | Such collaborations are threat to GP’s job (ruin the clinic business). | 1st | 2 (3) | 3.1 | 1 | 0.740 | |
| 2nd | 2 (3) | 3.03 | 1 | ||||
| 2. | CP’s interventions will be projected as a challenge to GP’s clinical decisions. | 1st | 3 (5) | 4.0 | 2 | 0.858 | |
| 2nd | 3 (5) | 4.07 | 2 | ||||
| 3. | Such collaborations will lead to violation of GPs jurisdiction. | 1st | 5 (4) | 4.76 | 3 | 0.636 | |
| 2nd | 5 (4) | 4.69 | 3 | ||||
| 4. | There will be potential for overlapping roles between GP and CP. | 1st | 5 (5) | 5.21 | 4 | 0.755 | |
| 2nd | 5 (5) | 5.21 | 4 | ||||
| 5. | CPs are more product than patient-oriented. | 1st | 6 (4) | 5.59 | 5 | 0.861 | |
| 2nd | 6 (4) | 5.59 | 5 | ||||
| 6. | Concerns regarding liability over patient’s information (in shared responsibility). | 1st | 5 (5) | 5.62 | 6 | 0.858 | |
| 2nd | 5 (5) | 5.62 | 6 | ||||
| 7. | CPs do not have the appropriate training in providing patient-oriented care services. | 1st | 6 (4) | 5.97 | 7 | 0.958 | |
| 2nd | 6 (4) | 5.97 | 7 | ||||
| 8. | GPs do not have time to discuss patient-related medicine issues with CP. | 1st | 7 (6) | 6.0 | 8 | 0.593 | |
| 2nd | 7 (6) | 6.0 | 8 | ||||
| 9. | Concern regarding patients’ privacy in community pharmacy setup. | 1st | 8 (5) | 7.0 | 9 | 0.948 | |
| 2nd | 8 (5) | 7.0 | 9 | ||||
| 10. | Malaysia does not have enough CPs to cater population health care needs. | 1st | 9 (4) | 7.76 | 10 | 0.793 | |
| 2nd | 9 (4) | 7.83 | 10 | ||||
| 1st | |||||||
| 2nd | |||||||
| 1. | Collaboration between CP and GP cannot be achieved without ″dispensing separation″. | 1st | 1 (2) | 1.83 | 1 | 0.248 | |
| 2nd | 1 (1) | 1.76 | 1 | ||||
| 2. | Lack of trust and appreciation from GP. | 1st | 3 (2) | 2.72 | 2 | 0.893 | |
| 2nd | 3 (2) | 2.72 | 2 | ||||
| 3. | GP does not consider CP’s advice as important. | 1st | 3 (3) | 3.38 | 3 | 0.584 | |
| 2nd | 3 (3) | 3.45 | 3 | ||||
| 4. | Lack of incentive/remuneration for CPs for providing the service. | 1st | 3 (2) | 3.59 | 4 | 0.566 | |
| 2nd | 3 (2) | 3.59 | 4 | ||||
| 5. | CPs have no time because of heavy workloads of other tasks, such as managing the shop and staff. | 1st | 5 (3) | 5.55 | 5 | 0.893 | |
| 2nd | 5 (3) | 5.55 | 5 | ||||
| 6. | CPs are not ready to advance their roles in collaborative practice. | 1st | 6 (3) | 5.97 | 6 | 0.887 | |
| 2nd | 6 (3) | 5.97 | 6 | ||||
| 7. | CPs do not have expertise to offer such services. | 1st | 7 (2) | 6.41 | 7 | 0.792 | |
| 2nd | 7 (2) | 6.41 | 7 | ||||
| 8. | CPs are comfortable with their current roles. | 1st | 7 (3) | 6.55 | 8 | 0.887 | |
| 2nd | 7 (3) | 6.55 | 8 | ||||
| 1st | |||||||
| 2nd | |||||||
| 1. | Consumers are still GP-centered and may not prefer to approach CP. | 1st | 2 (1) | 1.93 | 1 | 0.617 | |
| 2nd | 2 (1) | 1.93 | 1 | ||||
| 2. | Consumers are not aware of CP’s such advance roles. | 1st | 3 (2) | 2.34 | 2 | 0.780 | |
| 2nd | 3 (2) | 2.34 | 2 | ||||
| 3. | Increased cost to consumers due to additional CP’s consultation. | 1st | 2 (2) | 2.38 | 3 | 0.839 | |
| 2nd | 2 (2) | 2.38 | 3 | ||||
| 4. | Consumers will not trust CPs professional training and skills to perform such services. | 1st | 4 (1) | 3.34 | 4 | 0.744 | |
| 2nd | 4 (1) | 3.34 | 4 | ||||
| 1st | |||||||
| 2nd | |||||||
| 1. | Diabetes | 1st | 4 (1) | 1.55 | 1 | 0.816 | |
| 2nd | 4 (1) | 1.55 | 1 | ||||
| 2. | Hypertension | 1st | 3 (1) | 2.1 | 2 | 0.651 | |
| 2nd | 3 (1) | 2.1 | 2 | ||||
| 3. | Asthma/COPD | 1st | 1 (1) | 2.76 | 3 | 0.642 | |
| 2nd | 1 (1) | 2.76 | 3 | ||||
| 4. | Depression | 1st | 5 (1) | 4.48 | 4 | 0.793 | |
| 2nd | 5 (1) | 4.48 | 4 | ||||
| 5. | Cancer | 1st | 2 (2) | 4.86 | 5 | 0.683 | |
| 2nd | 2 (2) | 4.86 | 5 | ||||
| 6. | AIDS | 1st | 5 (2) | 5.24 | 6 | 0.670 | |
| 2nd | 5 (2) | 5.24 | 6 | ||||
| 1st | |||||||
| 2nd | |||||||
| 1. | Universal health coverage | 1st | 2 (2) | 2.34 | 1 | 0.405 | |
| 2nd | 2 (2) | 2.24 | 1 | ||||
| 2. | Third party payer/health insurance coverage | 1st | 2 (1) | 2.45 | 2 | 0.834 | |
| 2nd | 2 (1) | 2.45 | 2 | ||||
| 3. | Direct billing/ Fee for service | 1st | 3 (4) | 3.34 | 3 | 0.718 | |
| 2nd | 3 (3) | 3.45 | 3 | ||||
| 4. | Pay for performance | 1st | 4 (2) | 4.0 | 4 | 0.762 | |
| 2nd | 4 (2) | 4.0 | 4 | ||||
| 5. | Cost sharing | 1st | 4 (2) | 4.1 | 5 | 0.691 | |
| 2nd | 4 (2) | 4.1 | 5 | ||||
| 6. | Capitation | 1st | 6 (1) | 6.38 | 6 | 0.650 | |
| 2nd | 6 (1) | 6.38 | 6 | ||||
| 7. | Bundle payment | 1st | 7 (2) | 6.62 | 7 | 0.965 | |
| 2nd | 7 (2) | 6.62 | 7 | ||||
| 8. | Incident to service | 1st | 7 (2) | 6.76 | 8 | 0.867 | |
| 2nd | 7 (2) | 6.76 | 8 | ||||
| 1st | |||||||
| 2nd | |||||||
CP = community pharmacist, GP = general practitioner, CMTM = Collaborative Medication Therapy Management, COPD = Chronic Obstructive Pulmonary Disease, AIDS = Acquired Immune Deficiency Syndrome, IQR = interquartile range, UHC = Universal Health Coverage, Q1 and Q3 = quartiles, Kendall’s W = Kendall’s coefficient of concordance.
Intra-class correlation coefficient (ICC) test results.
| Intra-class correlation coefficient (ICC) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Themes | Round 1 | Round 2 | ||||||||
| Value | 95% CI | p-value | F-test | Verdict | Value | 95% CI | p-value | F-test | Verdict | |
| 0.62 | 0.364–0.821 | <0.001 | 3.35 | Good | 0.62 | 0.371–0.823 | <0.001 | 3.34 | Good | |
| 0.54 | 0.159–0.859 | <0.001 | 2.96 | Good | 0.50 | 0.100–0.842 | <0.001 | 2.68 | Good | |
| 0.19 | -0.071–0.535 | <0.001 | 1.57 | Poor | 0.13 | -0.127–0.482 | <0.001 | 1.35 | Poor | |
| 0.87 | 0.712–0.961 | <0.001 | 6.98 | Excellent | 0.86 | 0.724–0.963 | <0.001 | 7.28 | Excellent | |
| 0.98 | 0.942–0.994 | <0.001 | 35.61 | Excellent | 0.98 | 0.943–0.994 | <0.001 | 36.39 | Excellent | |
| 0.90 | 0.642–0.993 | <0.001 | 7.68 | Excellent | 0.90 | 0.642–0.993 | <0.001 | 7.68 | Excellent | |
| 0.82 | 0.662–0.935 | <0.001 | 7.01 | Excellent | 0.81 | 0.638–0.930 | <0.001 | 6.40 | Excellent | |
| 0.96 | 0.886–0.993 | <0.001 | 36.35 | Excellent | 0.96 | 0.882–0.992 | <0.001 | 34.37 | Excellent | |
| 0.99 | 0.965–0.998 | <0.001 | 63.58 | Excellent | 0.99 | 0.965–0.998 | <0.001 | 63.58 | Excellent | |
| 0.87 | 0.798–0.925 | <0.001 | 9.44 | Excellent | 0.87 | 0.791–0.922 | <0.001 | 9.17 | Excellent | |
| 0.98 | 0.943–0.994 | <0.001 | 36.36 | Excellent | 0.98 | 0.944–0.994 | <0.001 | 37.17 | Excellent | |
Type A; ICC using an absolute agreement definition using a two-way mixed model, Interpretation of results as: Poor agreement < 0.5, Moderate agreement = between 0.5 and 0.75, Good agreement = between 0.75 and 0.9, Strong agreement> 0.9. CI = confidence interval.
Fig 4The proposed collaborative medication therapy management model.
MMA = Malaysian Medical Association, MoH = Ministry of Health, MPS = Malaysian Pharmaceutical Society, CMTM = Collaborative Medication Therapy Management, CP = community pharmacy, GP = general practitioner, UHC = Universal Health Coverage, CPD = Continuous Professional Development.